Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Biodexa Pharmaceuticals ( (BDRX) ) is now available.
On May 22, 2025, Biodexa Pharmaceuticals announced that its collaboration partner, Emtora Biosciences, received an additional $3.0 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) for the eRapa Phase 3 program in familial adenomatous polyposis (FAP), bringing the total CPRIT funding to $20.0 million. This grant will facilitate the inclusion of more clinical sites and expedite patient recruitment, potentially accelerating the availability of eRapa as a treatment option for FAP, a condition with no current therapeutic alternatives other than surgery. The Phase 3 study will be conducted in the US and Europe, involving 168 patients, and aims to address a significant market opportunity estimated at $7.3 billion.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for the treatment of diseases with unmet medical needs. The company’s lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. Biodexa is headquartered in Cardiff, UK.
Average Trading Volume: 1,550,712
Technical Sentiment Signal: Sell
Current Market Cap: $882.5K
Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.